|Healthcare Review: Halozyme Therapeutics, Keryx Biopharmaceuticals, Sunesis Pharmaceuticals & Cytori Therapeutics Are Top Movers|
|By Staff and Wire Reportds|
|Friday, 21 September 2012 13:17|
VIVUS, Inc.(NASDAQ:VVUS) shares dropped 9.57% to $21.43 after the company expects an opinion recommending against approval of the Marketing Authorization Application or MAA for Qsiva for obesity. The formal decision from the CHMP is anticipated following their October 2012 meeting. If a negative recommendation is issued in October, and depending on the nature of the objections, the company would either resubmit the MAA at a later date or appeal this decision and request a re-examination by the CHMP. Several healthcare stocks are making notable news at mid day on Friday.
Halozyme Therapeutics, Inc.(NASDAQ:HALO) shares surged 26.83% to $8.13 after ViroPharma and HALO announced the U.S. Food & Drug Administration has provided guidance enabling ViroPharma to resume clinical studies of the subcutaneous administration of Cinryze in combination with rHuPH20. The FDA has advised ViroPharma to amend the study protocol, allowing for increased laboratory sampling to monitor rHuPH20 antibody levels, and keep the Agency informed of elevated antibody levels during the treatment phase of the study.
Keryx Biopharmaceuticals(NASDAQ:KERX) shares jumped 13.71% to $2.83. Keryx‘s stock had its “outperform” rating reaffirmed by research analysts at Oppenheimer in a report released on Sept. 5. Additionally, analysts predict that Keryx Biopharmaceuticals will post $-0.30 earnings per share for the current fiscal year. KERX is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease.
Sunesis Pharmaceuticals, Inc.(NASDAQ:SNSS) shares climbed 9.31% to $5.52 after Cowen reaffirmed their outperform rating on shares of SNSS in a research note released today.
Additionally, the company announced the closing of two previously disclosed financings. Royalty Pharma has invested $25.0 million under its royalty arrangement with Sunesis, and, in a separate transaction, a syndicate of lenders have funded the second tranche of $15.0 million under their $25.0 million loan facility with the company.
Cytori Therapeutics Inc. (USA)(NASDAQ:CYTX) stock jumped 7.51% to $4.58. The company announced that its Chief Executive Officer, Mr. Christopher Calhoun, will present at Noble Financial Capital Markets' BIOX Life Sciences Exposition to be held at the University of Connecticut, Stamford Campus on September 24 at 9:30 AM ET.
Dyax Corp.(NASDAQ:DYAX) shares climbed 6.75% to $2.69 in the early hour. Dyax Corp and Kadmon Corporation, LLC (Kadmon) announced that they have entered into a strategic licensing agreement in which Kadmon has been granted an exclusive worldwide license for the development and commercialization of the fully human monoclonal antibody DX-2400, a potent and selective antibody inhibitor of matrix metalloproteinase 14 (MMP-14).